Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TELA Bio, Inc. (TELA : NSDQ)

• Company Description    TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices. TELA Bio Inc. is headquartered in Malvern, Pennsylvania. Number of Employees: 209

• Price / Volume Information    Yesterday's Closing Price: $2.04 Daily Weekly Monthly 20 Day Moving Average: 86,505 shares Shares Outstanding: 39.56 (millions) Market Capitalization: $80.69 (millions) Beta: 0.90 52 Week High: $5.18 52 Week Low: $0.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.62% -1.05% 12 Week 117.02% 82.07% Year To Date -32.45% -36.73%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 GREAT VALLEY PARKWAY SUITE 24 - MALVERN,PA 19355 USA ph: 484-320-2930 fax: - ir@telabio.com http://www.telabio.com

• General Corporate Information    Officers Antony Koblish - President; Chief Executive Officer and Director Doug Evans - Chairman; Board of Directors Roberto Cuca - Chief Operating Officer and Chief Financial Office Megan Smeykal - Chief Accounting Officer and Controller Kurt Azarbarzin - Director Peer Information TELA Bio, Inc. (CORR.) TELA Bio, Inc. (RSPI) TELA Bio, Inc. (CGXP) TELA Bio, Inc. (BGEN) TELA Bio, Inc. (GTBP) TELA Bio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 872381108 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 39.56 Most Recent Split Date: (:1) Beta: 0.90 Market Capitalization: $80.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.71 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.45 Price/Cash Flow: - Price / Sales: 1.13 EPS Growth vs. Year Ago Period: -8.70% vs. Previous Quarter: -8.70% Sales Growth vs. Year Ago Period: 11.55% vs. Previous Quarter: 4.94% ROE 06/30/25 - - 03/31/25 - -402.45 12/31/24 - -383.78 ROA 06/30/25 - - 03/31/25 - -62.73 12/31/24 - -55.72 Current Ratio 06/30/25 - - 03/31/25 - 4.22 12/31/24 - 5.01 Quick Ratio 06/30/25 - - 03/31/25 - 3.40 12/31/24 - 4.19 Operating Margin 06/30/25 - - 03/31/25 - -61.00 12/31/24 - -54.60 Net Margin 06/30/25 - - 03/31/25 - -61.00 12/31/24 - -54.60 Pre-Tax Margin 06/30/25 - - 03/31/25 - -61.13 12/31/24 - -54.81 Book Value 06/30/25 - - 03/31/25 - 0.46 12/31/24 - 0.72 Inventory Turnover 06/30/25 - - 03/31/25 - 1.74 12/31/24 - 1.68 Debt-to-Equity 06/30/25 - - 03/31/25 - 2.28 12/31/24 - 1.45 Debt-to-Capital 06/30/25 - - 03/31/25 - 69.49 12/31/24 - 59.10

Powered by Zacks Investment Research ©